Effect of Combined Treatment With Folic Acid, Vitamin B 6 , and Vitamin B 12 on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women

Autor: Nancy R. Cook, JoAnn E. Manson, William G. Christen, Elaine Zaharris, Martin Van Denburgh, Christine M. Albert
Rok vydání: 2018
Předmět:
Time Factors
Antioxidant
Homocysteine
medicine.medical_treatment
030204 cardiovascular system & hematology
Fibrinogen
Gastroenterology
endothelial dysfunction
chemistry.chemical_compound
0302 clinical medicine
cardiovascular disease
randomized trial
Secondary Prevention
030212 general & internal medicine
Preventive Cardiology
Endothelial dysfunction
Original Research
Diet and Nutrition
Vitamins
Middle Aged
3. Good health
Drug Combinations
Vitamin B 12
Treatment Outcome
Cardiovascular Diseases
Female
Inflammation Mediators
medicine.symptom
Cardiology and Cardiovascular Medicine
medicine.drug
medicine.medical_specialty
B vitamins
Inflammation
Placebo
03 medical and health sciences
Folic Acid
Double-Blind Method
Internal medicine
medicine
Humans
Women
Vitamin B12
Aged
business.industry
biomarkers
medicine.disease
Vitamin B 6
chemistry
Endothelium
Vascular
business
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
ISSN: 2047-9980
DOI: 10.1161/jaha.117.008517
Popis: Background The aim of this study was to determine whether reducing plasma homocysteine concentrations with long‐term, combined treatment with folic acid, vitamin B 6 , and vitamin B 12 alters plasma biomarkers of inflammation and endothelial dysfunction in women at increased risk of cardiovascular disease. Methods and Results We conducted a blood substudy of 300 treatment‐adherent participants (150 in the active treatment group, 150 in the placebo group) in the WAFACS (Women's Antioxidant and Folic Acid Cardiovascular Study), a randomized, double‐blind, placebo‐controlled trial testing a daily combination of folic acid (2.5 mg), vitamin B 6 (50 mg), vitamin B 12 (1 mg), or matching placebo, in cardiovascular disease prevention among women at increased risk of cardiovascular disease. Plasma concentration of 3 biomarkers of inflammation (C‐reactive protein, interleukin‐6, and fibrinogen) and a biomarker of endothelial dysfunction (intercellular adhesion molecule 1) were measured at baseline and at the end of treatment and follow‐up. After 7.3 years of combined treatment with folic acid, vitamin B 6 , and vitamin B 12 , homocysteine concentrations were reduced by 18% in the active treatment group as compared with the placebo group ( P P =0.77), interleukin‐6 ( P =0.91), intercellular adhesion molecule 1 ( P =0.38), or fibrinogen ( P =0.68). Conclusions These findings indicate that long‐term, combined treatment with folic acid, vitamin B 6 , and vitamin B 12 lowers homocysteine concentrations, but does not alter major biomarkers of vascular inflammation, consistent with the lack of clinical cardiovascular disease benefit in the trial. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00000541.
Databáze: OpenAIRE
Externí odkaz: